Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment," at 4:40 p.m. ET, and in a subsequent update, incorrectly ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Shares of this drugmaker have returned -4.3% over the past month versus the Zacks S&P 500 composite's -3.5% change. The Zacks Large Cap Pharmaceuticals industry, to which Lilly belongs, has lost 5.6% ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion ...

New York Giants fandom is a visceral hodgepodge of ups and downs. It’s an experience that can send your spirit into the stratosphere off the high of a Superbowl win.

Claro Advisors LLC cut its stake in MercadoLibre, Inc. (NASDAQ:MELI – Free Report) by 6.8% in the fourth quarter, according ...

Tony Pietrowski’s Corbin Redhounds took their first step in defending their 50th District championship by earning their first ...

Novo Nordisk (NVO), and Viking Therapeutics (VKTX) all experienced significant declines on Tuesday, following disappointing ...

The latest edition of STAT’s Health Tech newsletter brings you important dispatches from the J.P. Morgan Health Care ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...